http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
구기환 ( Ki Hwan Ku ),박선자 ( Seun Ja Park ),김재현 ( Jae Hyun Kim ),권혜정 ( Hye Jung Kwon ),장희경 ( Hee Kyung Chang ),박정구 ( Jung Gu Park ) 대한소화기학회 2017 대한소화기학회지 Vol.70 No.6
Recurrence of gastric cancer after 10 years of surgical resection is highly rare. There are limited data on the surveillance of patients with gastric cancer after 10 years from gastrectomy. A 50-year-old man presented to the gastroenterology clinic at our hospital for the management of abnormal findings on a routine colonoscopic exam. He had undergone gastrectomy for advanced gastric cancer 12 years ago. At presentation, colonoscopic examination revealed asymmetrically edematous and hyperemic mucosal change with luminal narrowing on transverse colon. Abdominal computed tomography showed no evidence of distant metastasis, except for focal bowel wall thickening on transverse colon. He underwent a laparoscopic right-hemicolectomy, and the resected specimen revealed a recurrent and metastatic lesion. We report a case of recurrence of gastric cancer after 10 years from surgical resection with relevant literature review. (Korean J Gastroenterol 2017;70:296-300)
Peripheral T Cell Lymphoma에 선행하여 발생한 호산구성 근막염 유사 반응
구기환 ( Ki Hwan Ku ),김희규 ( Hee Kyoo Kim ),이호섭 ( Ho Sup Lee ),김근태 ( Geun Tae Kim ),옥철호 ( Chul Ho Ok ),정만홍 ( Maan Hong Jung ),장희경 ( Hee Kyung Chang ),천봉권 ( Bong Kwon Chun ) 대한천식알레르기학회 2010 천식 및 알레르기 Vol.30 No.3
Eosinophilic fasciitis (EF) is characterized by scleroderma-like skin lesions, peripheral eosinophilia and hypergamma-globulinemia. While EF is generally benign course, it may precede hematologic malignancy or Hodgkin`s disease, association with peripheral T-cell lymphoma (PTCL) is extremely rare. A 49-year-old man with edema and induration of both distal extremities. Peripheral blood eosinophil count was 2,530/μL. We suspected EF, however, could not performed histological diagnosis due to his refusal. After 6 months, he was suffered of abrupt fever, weight loss and general weakness for 1 months. Erythematous nodular papules of skin and enlarged inguinal lymph nodes were noted. Biopsies from skin and lymph node showed peripheral T cell lymphoma. (Korean J Asthma Allergy Clin Immunol 2010;30:233-236)
류마티스관절염에 병발한 국소형 Castleman병 1예
최윤정 ( Youn Jung Choi ),구기환 ( Ki Hwan Ku ),권혜정 ( Hye Jung Kwon ),박동현 ( Dong Hyun Park ),김근태 ( Geun Tae Kim ) 대한류마티스학회 2012 대한류마티스학회지 Vol.19 No.6
Castleman`s disease is an atypical lymphoproliferative disorderof unknown origin. It has three histologic types (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric). Some systemic diseases may be accompanied with Castleman`s disease, but it is unclear if Castleman`s disease is relevant to rheumatoid arthritis. We experienced a case of Castleman`s disease suffering from rheumatoid arthritis. A 25-year-old female with rheumatoid arthritis was referred to our hospital with a palpable mass lesion in the left upper arm. Excisional biopsy of the mass and arthroscopic synovectomy were performed, and the histological finding was compatible with hyaline-vascular type of Castleman`s disease. Herein, we report this case along with brief review of relevant literature.
진행성 대장암 환자에서 FOLFOX4 복합화학약물 치료의 실패 후 2차 요법으로 FOLFIRI 복합화학약물 치료의 효과와 안전성
김재현 ( Jae Hyun Kim ),박선자 ( Seun Ja Park ),박무인 ( Moo In Park ),문원 ( Won Moon ),김성은 ( Sung Eun Kim ),구기환 ( Ki Hwan Ku ),송성은 ( Sung Eun Song ),김제훈 ( Je Hun Kim ) 대한소화기학회 2014 대한소화기학회지 Vol.63 No.1
Background/Aims: The incidence of colorectal cancer has been increasing every year in Korea. Irinotecan- or oxaliplatin-based regimens including biologic agents are known to be effective in patients with advanced colorectal cancer. But in practice, FOLFOX (combination of oxaliplatin, 5-fluorouracil, and leucovorin) or FOLFIRI (combination of irinotecan, 5-fluorouracil, and leucovorin) regimens without biologic agents are more commonly used in Korea due to of the high costs of biologic agents. The aim of this study was to evaluate the efficacy and toxicity of FOLFIRI following FOLFOX4 in patients with advanced colorectal cancer. Methods: A total of 54 patients with advanced colorectal cancer who were treated between May 2005 and May 2013 with FOLFOX4 as first-line chemotherapy and with FOLFIRI as second-line chemotherapy at Kosin University Gospel Hospital (Busan, Korea) were reviewed retrospectively. Results: A total of 54 patients received second-line FOLFIRI chemotherapy. Five patients (9.3%) had a partial response, 29 patients (53.7%) had a stable disease. The median overall survival was 8.90 months and the median time to progression was 4.33 months. Toxicities were tolerable. Conclusions: In a Korean population, FOLFIRI as second-line chemotherapy is effective and well tolerated in patients with advanced colorectal cancer after failure of FOLFOX4. Although the efficacy of FOLFIRI in this study was lower than that of second-line FOLFIRI with biologic agents, these results can help in the formulation of a treatment strategy for financially troubled patients. (Korean J Gastroenterol 2014;63:18-24)
위장관에 발현한 고립 골수외 형질세포종: 두 증례 보고 및 문헌 고찰
한유진 ( You Jin Han ),박선자 ( Seun Ja Park ),박무인 ( Moo In Park ),문원 ( Won Moon ),김성은 ( Sung Eun Kim ),구기환 ( Ki Hwan Ku ),옥소영 ( So Young Ock ) 대한소화기학회 2014 대한소화기학회지 Vol.63 No.5
Solitary extramedullary plasmacytoma (EMP) is a plasma cell neoplasm without bone marrow involvement. EMPs are rare in the gastrointestinal (GI) tract. We report two cases of primary EMP, one in the transverse colon and the other in the stomach. In the first case, a mass on the transverse colon was found on colonoscopy. The patient underwent left hemicolectomy and has been followed-up for 3 years without recurrence postoperatively. The latter case had several masses in the stomach. The patient underwent bypass surgery and has received supportive care for 1 month. Histopathologic specimens of both the cases showed a monoclonal lambda chain EMP. Subsequent investigations included a bone marrow biopsy, serum IgA, IgG, IgM and serum protein electrophoresis, and the results were negative for multiple myeloma in both the cases. Solitary EMP in the GI tract can be mistaken for colon cancer or stomach cancer on endoscopy; therefore, a sufficient number of biopsy specimens can help diagnose solitary EMPs. Surgical resection alone or with radiation therapy in cases with positive surgical margin is currently the only treatment for solitary EMP in the GI tract. Further study is necessary to determine disease prognosis and to investigate other treatment methods.
진행성 위암 환자에서 1차 요법으로 FOLFOX-4 병합화학 약물치료의 효과와 안정성
이천우 ( Cheon Woo Lee ),박무인 ( Moo In Park ),박선자 ( Seun Ja Park ),문원 ( Won Moon ),김형훈 ( Hyung Hun Kim ),이혜원 ( Hae Won Lee ),구기환 ( Ki Hwan Ku ),김부경 ( Bu Kyung Kim ) 대한내과학회 2012 대한내과학회지 Vol.82 No.1
This study examined the efficacy and safety of oxaliplatin-5-fluorouracil-Leucovorin (FOLFOX-4) combination chemotherapy as first-Line treatment in patients with advanced gastric cancer. This retrospective study enrolled 35 patients diagnosed with pathologically proven surgically unresectable gastric cancer who received FOLFOX-4 combination chemotherapy between August 2006 and February 2009, using medical records. The administered dose of oxaliplatin was 85 mg/㎡ for 2 hrs and Leucovorin 200 mg/㎡ for 2 hrs on day 1, 5-fluorouracil 400 mg/㎡ as a bolus and 5-fluorouracil 600 mg/㎡ for 22 hrs on days 1 and 2, every 2 weeks. The response was assessed every three cycles. Toxicity was evaluated for every course of chemotherapy according to the NCI toxicity criteria ver. 2.0. The median patient age was 61 (range 27-77) years. The median overall survival was 8.50 (6.23-10.90) months and the median time to progression was 4.50 (0.38-9.75) months. With FOLFOX-4, there was no complete remission and 19 partial responses, for a response rate of 54.3%. Over 298 cycles, anemia worse than NCI toxicity grade 3 occurred in 1.3%, Leukopenia in 1.6%, neutropenia in 9%, and thrombocytopenia in 3.2%. Grade 1-2 neuropathy occurred in 14.7% of the cycles. Neutropenic fever occurred in two cycles and the regimen was changed because of side effects in one FOLFOX-4 has a very high response rate with mild toxicity in patients with advanced gastric cancer as a first-Line treatment. (Korean J Med 2012;82:37-44)